Companies/Pulse Biosciences, Inc.

Company profile

Pulse Biosciences, Inc.

NASDAQ: PLSE · Healthcare · Medical - Instruments & Supplies

PublicHQ Miami, CACIK 0001625101Reports USD

#948 of 1,394 Healthcare companies by revenue

EA Score

43D

FH 45DQ 35GM —SS 64

v0.1 · 55/100 weight · provisional

↑ Altman-Z, balance-sheet leverage · ↓ operating margin, net margin

Methodology →

Revenue TTM

$751.0k

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$72.8M

Employees

Market cap

$2.0B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$350.0k$350.0k2025

Net income-$72.8M-$72.8M2025

Operating income-$76.9M-$76.9M2025

Total assets$94.5M$94.5M2025

Liabilities$13.9M$13.9M2025

Equity$80.7M$80.7M2025

Revenue trend

FY2022 – FY2025 · USD

FY22

$1.4M

FY21

$700.0k

FY22

FY23

FY24

$350.0k

FY25

Revenue by segment

Filed disclosures · FY2022

By product

Cycle Units Products100%

By geography

North America74%

Rest of World26%

The read

Pulse Biosciences, Inc. booked $350.0k in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -20794.6% net margin.

Peers · Healthcare

Neogen Corporation65B Butterfly Network, Inc.61C Aurinia Pharmaceuticals Inc.77B+Sarepta Therapeutics, Inc.69B

Key facts

CEOPaul Arthur LaViolette

SectorHealthcare

IndustryMedical - Instruments & Supplies

HeadquartersMiami, CA

ExchangeNASDAQ: PLSE

Employees75

IPO date2016-05-18

Latest filings

8-K2026-06-12 8-K2026-06-10 10-Q2026-05-14 DEF 14A2026-05-11 8-K2026-05-06 8-K2026-05-04 8-K2026-04-27 8-K2026-04-16

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.